Karuna Therapeutics, Inc. ((KRTX)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Study Overview: Karuna Therapeutics, Inc. is conducting a Phase 3 global, multicenter, open-label extension study titled ‘A Phase 3 Global, Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer’s Disease.’ The primary objective is to evaluate the long-term safety and tolerability of KarXT in patients experiencing psychosis related to Alzheimer’s Disease, highlighting its significance in addressing a critical aspect of Alzheimer’s care.
Intervention/Treatment: The study tests KarXT, an experimental drug composed of Xanomeline and Trospium Chloride. It aims to manage psychosis symptoms in Alzheimer’s patients, offering a potential new treatment avenue.
Study Design: This interventional study follows a single-group assignment model without masking, focusing on treatment as the primary purpose. Participants from previous related studies are eligible to join this open-label extension to further assess the drug’s safety over a longer period.
Study Timeline: The study began on July 11, 2023, with recruitment currently ongoing. The last update was submitted on August 11, 2025, indicating the study’s active status and progression towards completion.
Market Implications: The ongoing study of KarXT could positively influence Karuna Therapeutics’ stock performance by showcasing the company’s commitment to addressing Alzheimer’s-related psychosis. Successful outcomes may enhance investor confidence and position Karuna favorably against competitors in the Alzheimer’s treatment market.
The study is actively recruiting, with further details available on the ClinicalTrials portal.